Eli Lilly has agreed to acquire Scorpion Therapeutics’ breast cancer treatment program for up to $2.5 billion in cash. The drugmaker said Monday it is acquiring Scorpion and its STX-478 program ...

Now that the year is underway and a new presidential administration is in place in Washington, let’s consider the environment ...

The company states: “Eli Lilly (LLY) and Scorpion Therapeutics announced a definitive agreement for Lilly to acquire Scorpion’s PI3Kalpha inhibitor program STX-478. STX-478 is a once-daily ...

Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a cancer therapy being developed by Scorpion Therapeutics in a third major transaction announced on the first day of the JP Morgan ...

You have permission to edit this article. Edit Close Activate Subscribe My Account Logout Login/Register ...

Eli Lilly and RNAi therapeutics specialist OliX Pharmaceuticals have entered into a global licensing agreement to advance a ...

Eli Lilly and Co.’s end last year to its PI3Kα inhibitor program didn’t mean the pharma player was giving up on the target – ...

Plymouth drugmaker IDRx was bought by GSK plc (NYSE: GSK) for $1 billion upfront, while Eli Lilly and Co. paid Boston-based Scorpion Therapeutics Inc. up to $2.5 billion for its lead cancer drug.

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.